Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression in p...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Chen-Yu Hu, Xiang-Ming Xu, Bo Hong, Zhi-Gang Wu, Yun Qian, Tian-Hao Weng, Yi-Zhi Liu, Tao-Ming Tang, Ming-Hai Wang, Hang-Ping Yao
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2019-12-01
Serie:	Frontiers in Oncology
Soggetti:	pancreatic cancer tyrosine kinase inhibitors RON receptor tyrosine kinase MET receptor tyrosine kinase prognosis biomarker therapeutic target
Accesso online:	https://www.frontiersin.org/article/10.3389/fonc.2019.01377/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!